A phase IB/IIA study of the safety and activity of intravenous isophosphoramide mustard (ZIO-201) in patients with advanced sarcoma
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Palifosfamide (Primary)
- Indications Osteosarcoma; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 17 Jul 2012 Additional lead trial investigator (Lewis J) added as reported by ClinicalTrials.gov.
- 13 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Nov 2008 New source identified and integrated (ZIOPHARM Oncology media release).